TY - JOUR
T1 - Role of Immunotherapy in Advanced Gastroesophageal Cancer
AU - Terrero, Gretel
AU - Lockhart, A. Craig
N1 - Publisher Copyright:
© 2020, Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2020/11/1
Y1 - 2020/11/1
N2 - Purpose of Review: Immunotherapy and tumor microenvironment have been at the forefront of cancer research over the past several decades. Here, we will review the role of immunotherapy in advanced gastroesophageal cancers including targeted antibodies, immunomodulating agents, vaccines, oncolytic virus therapy, and adoptive immunotherapy, and discuss the future direction for immunotherapy in this population. Recent Findings: Targeted antibodies are already standard-of-care. An anti-PD-1 monoclonal antibody is currently FDA approved for second-line treatment of locally advanced or metastatic ESCC, as well as beyond second-line treatment of advanced G/GEJ cancers, and recent data suggests it may be considered in first-line treatment of advanced G/GEJ cancers. Combination therapies such as immunotherapy plus chemotherapy and/or radiotherapy, vaccines, oncolytic viral therapy, and adoptive immunotherapy in varying combinations are currently under active investigation. Summary: Several trials are ongoing and are hoped to reach more efficacious and individualized treatment options in advanced gastroesophageal cancer, where novel treatment options are desperately needed.
AB - Purpose of Review: Immunotherapy and tumor microenvironment have been at the forefront of cancer research over the past several decades. Here, we will review the role of immunotherapy in advanced gastroesophageal cancers including targeted antibodies, immunomodulating agents, vaccines, oncolytic virus therapy, and adoptive immunotherapy, and discuss the future direction for immunotherapy in this population. Recent Findings: Targeted antibodies are already standard-of-care. An anti-PD-1 monoclonal antibody is currently FDA approved for second-line treatment of locally advanced or metastatic ESCC, as well as beyond second-line treatment of advanced G/GEJ cancers, and recent data suggests it may be considered in first-line treatment of advanced G/GEJ cancers. Combination therapies such as immunotherapy plus chemotherapy and/or radiotherapy, vaccines, oncolytic viral therapy, and adoptive immunotherapy in varying combinations are currently under active investigation. Summary: Several trials are ongoing and are hoped to reach more efficacious and individualized treatment options in advanced gastroesophageal cancer, where novel treatment options are desperately needed.
KW - Advanced esophageal cancer
KW - Advanced gastric cancer
KW - Advanced gastroesophageal cancer
KW - Immunotherapy
KW - PD-1
KW - PD-L1
UR - http://www.scopus.com/inward/record.url?scp=85089437440&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85089437440&partnerID=8YFLogxK
U2 - 10.1007/s11912-020-00975-y
DO - 10.1007/s11912-020-00975-y
M3 - Review article
C2 - 32803457
AN - SCOPUS:85089437440
VL - 22
JO - Current Oncology Reports
JF - Current Oncology Reports
SN - 1523-3790
IS - 11
M1 - 112
ER -